Article
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
The New England journal of medicine - 5 Jan 2023
Strickler John H, Satake Hironaga, George Thomas J, Yaeger Rona, Hollebecque Antoine, Garrido-Laguna Ignacio, Schuler Martin, Burns Timothy F, Coveler Andrew L, Falchook Gerald S, Vincent Mark, Sunakawa Yu, Dahan Laetitia, Bajor David, Rha Sun-Young, Lemech Charlotte, Juric Dejan, Rehn Marko, Ngarmchamnanrith Gataree, Jafarinasabian Pegah, Tran Qui, Hong David S
Abstract excerpt
BACKGROUND: KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown. METHODS: We conducted a single-group, phase 1-2 trial to assess the safety and efficacy of sotorasib treatment in patients with KRAS p.G12C-mutated pancreatic cancer who had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.